Bloomington, Ind. — Furthering their commitment to relentlessly delivering new products and services to address unmet customer needs, today Cook Medical announced a strategic investment in the urology space. Zenflow is a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH).
“This investment reflects our confidence in the future of Zenflow and the Spring® System technology. Zenflow is aligned with our core focus of developing minimally invasive technologies that restore flow,” said DJ Sirota, senior vice president of Cook Medical’s MedSurg division. “This type of agreement is yet another proof-point to how Cook is changing to focus on our future as product innovators.”
With funding led by Cook, Zenflow closed an $24 million Series C financing round today and included participation from existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners and others.
Funds will be used to support the company’s Pre-Market Approval (PMA) submission as well as to prepare for commercialization in order to set the stage for FDA approval of its Spring System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate. The Spring System was designed with the patient’s experience in mind and relies on a small spring-like coil to gently prop open the urethra, restoring its normal function while preserving the natural anatomy. Over 40 million patients suffer from BPH in the U.S.